Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06673017 · ClinicalTrials.gov registry record · Phase 1
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by PanTher Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 6
- Study locations
NCT06673017: Recruiting Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by PanTher Therapeutics.
NCT06673017 is a Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by PanTher Therapeutics. The registered enrollment target is 26 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06673017, a Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by PanTher Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).
Primary Outcome
Number of subjects with PTM-101/PTM-101 placement-related adverse events as assessed by CTCAE v5.0
Conditions Studied
Interventions
- DRUG PTM-101
Study Locations (6)
Texas
- University of Texas Southwestern Medical Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
Michigan
- Karmanos Cancer Institute - Detroit
New York
- Northwell Health Zuckerberg Cancer Center - Lake Success
Washington
- Virginia Mason Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2025-04-14 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
What NCT06673017 shows while recruiting
NCT06673017 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower).
The record links to 4 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which PTM-101 is the first listed.
NCT06673017 lists 6 locations in 5 states (Texas, California, Michigan).
Frequently Asked Questions
What is clinical trial NCT06673017 about?
NCT06673017 is a clinical study titled "PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)". This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).
What is the current status of trial NCT06673017?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2025-04-14. Estimated completion is 2028-06.
What conditions does trial NCT06673017 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT06673017?
The interventions under investigation include: PTM-101 (DRUG).
Who is sponsoring clinical trial NCT06673017?
This trial is sponsored by PanTher Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06673017 being conducted?
This trial has 6 study locations across California, Michigan, New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06673017's enrollment target sits among peer trials
26 205th of 278 higher than 70 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI